News
Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...
Asianet Newsable on MSN41m
Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The StockJaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback